Tranzyme, Inc. (TZYM) Reports Q4 Loss of $0.33, Sales Fall Short
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- S&P 500, Dow futures inch up before inflation data; bank results in focus
- Oil prices surge as Iran deploys new tactics to target tankers
- Bank of America stock falls on earnings miss
- BlackRock earnings beat sends shares higher premarket
- ASML shares climb on raised 2026 outlook, capacity expansion plans
Tweet
Share
E-mailGet Alerts TZYM Hot Sheet
Join SI Premium – FREE
Tranzyme, Inc. (NASDAQ: TZYM) reported Q4 EPS of ($0.33), $0.02 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.43 million.
For earnings history and earnings-related data on Tranzyme, Inc. (TZYM) click here.
For earnings history and earnings-related data on Tranzyme, Inc. (TZYM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlackRock earnings beat sends shares higher premarket
- Morgan Stanley (MS) Tops Q3 EPS by 9c
- ASML shares climb on raised 2026 outlook, capacity expansion plans
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
